2823 studies found for:    "Lymphoma, Non-Hodgkin"
Show Display Options
RSS Create an RSS feed from your search for:
"Lymphoma, Non-Hodgkin"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Conditions: Lymphoma, Non-Hodgkin;   Hodgkin Disease;   Multiple Myeloma
Interventions: Drug: TXA127;   Drug: Placebo
2 Not yet recruiting A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Ibrutinib;   Drug: Rituximab;   Drug: Ifosfamide;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Vincristine;   Drug: Idarubicin;   Drug: Dexamethasone
3 Recruiting Safety Study of SEA-CD40 in Cancer Patients
Conditions: Cancer;   Carcinoma;   Neoplasms;   Neoplasm Metastasis;   Hematologic Malignancies;   Hodgkin Disease;   Lymphoma;   Lymphoma, Non-Hodgkin;   Lymphoma, B-Cell;   Lymphoma, Large B-Cell, Diffuse
Intervention: Drug: SEA-CD40
4 Recruiting ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Conditions: Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell
Interventions: Drug: brentuximab vedotin;   Drug: doxorubicin;   Drug: prednisone;   Drug: vincristine;   Drug: cyclophosphamide
5 Completed A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Lymphoma, B-Cell;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell
Interventions: Drug: brentuximab vedotin;   Drug: rituximab
6 Available A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell, Cutaneous
Intervention: Drug: brentuximab vedotin
7 Terminated
Has Results
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit
Conditions: Leukemia, Lymphocytic, Acute;   Leukemia, Lymphocytic, Chronic;   Leukemia, Myelocytic, Acute;   Leukemia, Myeloid, Chronic;   Lymphoma, Non-Hodgkin;   Lymphoma, Hodgkins
Intervention: Biological: Haploidentical/cord transplant
8 Completed Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
Conditions: Carcinomas;   Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Neoplasms
Interventions: Drug: brentuximab vedotin;   Drug: rifampin;   Drug: midazolam;   Drug: ketoconazole
9 Completed A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma
Conditions: Carcinoma, Renal Cell;   Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-75
10 Recruiting Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Procedure: Stem cell infusion;   Procedure: TLI;   Drug: Anti-thymocyte globulin;   Drug: Solumedrol;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
11 Completed Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease
Conditions: Leukemia;   Lymphoma, Non-Hodgkin;   Hodgkin Disease;   Myelodysplastic Syndromes;   Multiple Myeloma
Interventions: Genetic: CD34-TK75 transduced donor lymphocytes;   Radiation: Sub Study - 18 FHBG PET/CT Scans
12 Active, not recruiting
Has Results
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
Conditions: Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
13 Completed
Has Results
Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma
Conditions: Lymphoma;   Hodgkin Disease;   Lymphoma, Non-Hodgkin
Intervention: Drug: PCI-24781
14 Completed Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin
Interventions: Drug: SGN-40;   Drug: rituximab;   Drug: gemcitabine
15 Terminated A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Interventions: Drug: SGN-35;   Drug: gemcitabine
16 Terminated
Has Results
T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE
Conditions: Leukemia;   Cancer;   Lymphoma;   Lymphoma, Hodgkin;   Lymphoma, Non-Hodgkin
Interventions: Drug: Ara C;   Drug: Mesna;   Drug: Cyclophosphamide;   Radiation: TBI-Total Body Irradiation
17 Completed Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
Conditions: Neoplasms by Site;   Lymphoma, Non-hodgkin;   Hodgkin Disease;   Multiple Myeloma;   Leukemia, Lymphocytic, Chronic
Intervention: Drug: PCI-24781
18 Terminated A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin
Interventions: Drug: SGN-40;   Drug: placebo;   Drug: rituximab;   Drug: etoposide;   Drug: carboplatin;   Drug: ifosfamide
19 Completed Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-40
20 Completed Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
Conditions: Lymphoma, Non-Hodgkin;   Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic
Intervention: Drug: SGN-35

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years